Mevrometostat not checked
Pfizer · PF-06821497 · EZH2i
FollowEvery change as it happens, and a Monday email
Trials
4 active
7 in total · 6 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate, Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC) and 1 more
- Main trialPhase 3
- “Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment. The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus…”In the company’s words, NCT06551324 on ClinicalTrials.gov
- Other names
- PF-06821497 · EZH2i
Other drugs for Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- ApalutamideJanssen Research & Development, LLC · Phase 3
- 64Cu-SAR-bisPSMAClarity Pharmaceuticals Ltd · Phase 3
- Abiraterone acetateJanssen Research & Development, LLC · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamidePfizer · Astellas · Phase 3
- Aglatimagene besadenovecCandel Therapeutics · Phase 3
Coming up4
- 28 Feb 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 Sep 2027Phase 3 trial completes · ClinicalTrials.gov
- 20 Apr 2028Phase 1 trial completes · ClinicalTrials.gov
- 12 Sep 2028Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 18 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT06629779
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 28 Feb 2027 | A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | |
| Phase 3Active, not recruiting | 30 Sep 2027 | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | |
| Phase 3Recruiting | 12 Sep 2028 | This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. | |
| Phase 1Recruiting | 20 Apr 2028 | A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | |
| Phase 1Completed | 20 Jun 2023 | A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants. | |
| Phase 1Completed | 11 Nov 2024 | A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body. | |
| Phase 1Withdrawn | 8 Sep 2025 | A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026